946 related articles for article (PubMed ID: 27550399)
61. Direct oral anticoagulants in rare venous thrombosis.
Finazzi G; Ageno W
Intern Emerg Med; 2016 Mar; 11(2):167-70. PubMed ID: 26875179
[TBL] [Abstract][Full Text] [Related]
62. Practical recommendations on incorporating new oral anticoagulants into routine practice.
Randhawa J; Thiruchelvam N; Ghobrial M; Spiro T; Clark B; Haddad A; Daw H
Clin Adv Hematol Oncol; 2014 Oct; 12(10):675-83. PubMed ID: 25658892
[TBL] [Abstract][Full Text] [Related]
63. A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism.
Comerota AJ; Ramacciotti E
Am J Med Sci; 2016 Jul; 352(1):92-106. PubMed ID: 27432042
[TBL] [Abstract][Full Text] [Related]
64. Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: a meta-analysis of randomized controlled trials.
Di Minno MN; Lupoli R; Di Minno A; Ambrosino P; Scalera A; Dentali F
Ann Med; 2015 Feb; 47(1):61-8. PubMed ID: 25665582
[TBL] [Abstract][Full Text] [Related]
65. Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials.
Rojas-Hernandez CM; Oo TH
Drugs; 2019 Apr; 79(6):621-631. PubMed ID: 30905033
[TBL] [Abstract][Full Text] [Related]
66. The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.
Jugrin AV; Ustyugova A; Urbich M; Lamotte M; Sunderland T
Thromb Haemost; 2015 Oct; 114(4):778-92. PubMed ID: 26272227
[TBL] [Abstract][Full Text] [Related]
67. Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis.
Vasanthamohan L; Boonyawat K; Chai-Adisaksopha C; Crowther M
J Thromb Haemost; 2018 Jul; 16(7):1288-1295. PubMed ID: 29772108
[TBL] [Abstract][Full Text] [Related]
68. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
69. Venous thromboembolism management: where do novel anticoagulants fit?
Spyropoulos AC; Turpie AG
Curr Med Res Opin; 2013 Jul; 29(7):783-90. PubMed ID: 23659584
[TBL] [Abstract][Full Text] [Related]
70. The discovery of dabigatran etexilate for the treatment of venous thrombosis.
Feuring M; van Ryn J
Expert Opin Drug Discov; 2016 Jul; 11(7):717-31. PubMed ID: 27159158
[TBL] [Abstract][Full Text] [Related]
71. Modern Treatment Modalities and Duration of Treatment for Venous Thromboembolism.
Robert-Ebadi H; Righini M
Ther Umsch; 2016; 73(10):618-625. PubMed ID: 28045360
[No Abstract] [Full Text] [Related]
72. Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Douketis J; Bell AD; Eikelboom J; Liew A
Can Fam Physician; 2014 Nov; 60(11):989-95. PubMed ID: 25392438
[TBL] [Abstract][Full Text] [Related]
73. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
74. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
Jugrin AV; Hösel V; Ustyugova A; De Francesco M; Lamotte M; Sunderland T
J Med Econ; 2016; 19(1):1-10. PubMed ID: 26390231
[TBL] [Abstract][Full Text] [Related]
75. Improving evidence on anticoagulant therapies for venous thromboembolism in children: key challenges and opportunities.
Goldenberg NA; Takemoto CM; Yee DL; Kittelson JM; Massicotte MP
Blood; 2015 Dec; 126(24):2541-7. PubMed ID: 26500341
[TBL] [Abstract][Full Text] [Related]
76. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review.
Bikdeli B; Zahedi Tajrishi F; Sadeghipour P; Talasaz AH; Fanikos J; Lippi G; Siegal DM; Eikelboom JW; Monreal M; Jimenez D; Connors JM; Ageno W; Barnes GD; Piazza G; Angiolillo DJ; Parikh SA; Kirtane AJ; Lopes RD; Bhatt DL; Weitz JI; Mehran R; Krumholz HM; Goldhaber SZ; Lip GYH
JAMA Cardiol; 2022 Jul; 7(7):747-759. PubMed ID: 35648414
[TBL] [Abstract][Full Text] [Related]
77. Impact of oral anticoagulation choice on healthcare utilization for the primary treatment of venous thromboembolism.
Lutsey PL; MacLehose RF; Claxton JS; Walker RF; Adam TJ; Alonso A; Zakai NA
Vasc Med; 2020 Dec; 25(6):549-556. PubMed ID: 32716254
[TBL] [Abstract][Full Text] [Related]
78. Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease.
Shaw J; de Wit C; Le Gal G; Carrier M
J Thromb Haemost; 2017 May; 15(5):925-930. PubMed ID: 28296069
[TBL] [Abstract][Full Text] [Related]
79. Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A meta-analysis of the interventional trials.
Loffredo L; Violi F; Perri L
Int J Cardiol; 2016 Jun; 212():255-8. PubMed ID: 27057930
[TBL] [Abstract][Full Text] [Related]
80. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
